Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma

This study is testing whether adding two immunotherapy drugs — tolecizumab (a PCSK9 inhibitor) and a PD-1/PD-L1 checkpoint inhibitor — to standard chemotherapy before surgery improves outcomes for patients with locally advanced colon cancer that has not yet been treated. **You may be eligible if...** - You have been confirmed by biopsy to have colon adenocarcinoma at a locally advanced stage (cT3c or higher) - You are between 18 and 80 years old - Your tumor is more than 10 cm from the anal opening (i.e., it is in the colon, not the rectum) - You have good overall physical function (ECOG 0 or 1) - You have not received any prior treatment for this cancer - You are not pregnant or breastfeeding **You may NOT be eligible if...** - You have had any prior treatment for this colon cancer - You have previously used PCSK9 inhibitors or PD-1/PD-L1 immunotherapy drugs - You have an active autoimmune disease or are taking immunosuppressants - You have a serious active infection requiring antibiotics - You have severe heart disease or other major health conditions - You have a complicated tumor (such as a perforation or bowel blockage) Talk to your doctor to see if this trial is right for you.